BrightPath Biotherapeutics Co., Ltd. reported consolidated earnings results for the six months ended September 30, 2017. For the period, the company reported net sales of JPY 182.683 million. Operating loss was JPY 685.920 million. Ordinary loss was JPY 685.187 million. Loss before income tax was JPY 685.187 million. Loss attributable to owners of parent was JPY 687.332 million or JPY 18.45 per share. Net cash used in operating activities was JPY 641.404 million. Purchase of property, plant and equipment was JPY 30.745 million. Purchase of intangible assets was JPY 1.375 million.

For the year ending March 31, 2018, on consolidated basis, the company expects net sales of JPY 280 million, operating loss of JPY 2,000 million, ordinary loss of JPY 2,000 million and loss attributable to owners of parents of JPY 2,000 million or 53.73 per share.